SuperworthVeradermics free cash flow MANE
Cash from operations less capital spending, by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$14.5M
Veradermics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$14.5M.
Free cash flow over time
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$14.5M | n/a | |
| Q1 FY26 | −$21.2M | n/a | |
| Q2 FY25 | −$15.6M | n/a | |
| Q1 FY25 | −$13.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Veradermics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| MANEVeradermics | n/m |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| LGNDLigand Pharmaceuticals | 2.2% |
| AMRXAmneal Pharmaceuticals | 2.0% |
| ALKSAlkermes plc. | 3.0% |
| INDVIndivior Pharmaceuticals | −2.7% |
| TGTXTG Therapeutics | 0.2% |
| ARQTArcutis Biotherapeutics | 1.0% |
| LQDALiquidia | 3.9% |
| PTGXProtagonist Therapeutics | 1.5% |
| CORTCorcept Therapeutics | 1.2% |
| Peer median | 1.7% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Veradermics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.